New drug TOS-358 targets Hard-to-Treat breast cancer in early trial
Disease control
Recruiting now
This early-stage trial tests a new drug called TOS-358 in women with advanced HR+ HER2- breast cancer that has a specific mutation in the PIK3CA gene. The study aims to find the safest dose and see if the drug works alone or with standard treatments like fulvestrant and CDK4/6 in…
Phase: PHASE1 • Sponsor: Totus Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC